Eosinophils in COPD: are we nearly there yet?,The Lancet Respiratory Medicine

当前位置： X-MOL 学术 › Lancet Respir. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Eosinophils in COPD: are we nearly there yet?
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2017-11-13 , DOI: 10.1016/s2213-2600(17)30445-9
Mona Bafadhel ₁

Affiliation

Large observational studies can improve our understanding of disease and inform as to the generalisability and interpretation of the results of the study. Detailed and repeated assessments of patients over time can give clarity on disease heterogeneity and temporal associations between outcomes of interest. Chronic obstructive pulmonary disease (COPD) is heterogeneous with respect to symptoms, physiology, inflammation, extrapulmonary effects, and response to treatments. In an age of precision medicine in which monoclonal antibodies have the potential to improve outcomes in treatment-resistant patients,^1,2 the identification of subgroups of patients in which treatments are effective could lead to personalised management of COPD.

中文翻译：

COPD中的嗜酸性粒细胞：我们快到了吗？

大型观察性研究可以提高我们对疾病的理解，并为研究结果的普遍性和解释提供信息。随着时间的推移对患者进行详细和重复的评估可以明确疾病异质性和感兴趣的结果之间的时间关联。慢性阻塞性肺病 (COPD) 在症状、生理、炎症、肺外效应和对治疗的反应方面具有异质性。在精准医学时代，单克隆抗体有可能改善耐药患者的预后，^1,2确定治疗有效的患者亚组可能会导致 COPD 的个体化管理。

更新日期：2017-11-14

点击分享查看原文

点击收藏

阅读更多本刊最新论文